Immediate Impact
1 by Nobel laureates 62 standout
Citing Papers
Strategic advancements in targeting the PI3K/AKT/mTOR pathway for Breast cancer therapy
2025 Standout
Present and future of cancer nano-immunotherapy: opportunities, obstacles and challenges
2025 Standout
Works of Dennis Williams being referenced
SPEARHEAD-1: A phase 2 trial of afamitresgene autoleucel (Formerly ADP-A2M4) in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma.
2021
Phase I dose escalation and expansion trial to assess the safety and efficacy of ADP-A2M4 SPEAR T cells in advanced solid tumors.
2020
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Dennis Williams | 96 | 76 | 31 | 71 | 21 | 322 | |
| H. Pflieger | 128 | 55 | 21 | 36 | 38 | 355 | |
| Richard Kaczmarski | 52 | 78 | 24 | 27 | 24 | 308 | |
| A. De Laurenzi | 85 | 46 | 6 | 141 | 21 | 300 | |
| Patricia Davenport | 25 | 25 | 46 | 49 | 27 | 349 | |
| So‐Yong Kwon | 17 | 46 | 37 | 56 | 26 | 280 | |
| David Ong | 31 | 67 | 3 | 98 | 18 | 345 | |
| Montserrat Rovira | 106 | 87 | 3 | 72 | 24 | 339 | |
| Soon Deok Park | 22 | 28 | 10 | 91 | 17 | 367 | |
| Adriana Koliski | 38 | 97 | 2 | 73 | 21 | 306 | |
| Tercan Us | 36 | 26 | 4 | 100 | 31 | 281 |
All Works
Loading papers...